- Home
- PRAA vs CVAC Comparison
PRAA vs CVAC Comparison
Compare PRAA & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAA
- CVAC
- Stock Information
- Founded
- PRAA 1996
- CVAC 2000
- Country
- PRAA United States
- CVAC Germany
- Employees
- PRAA N/A
- CVAC N/A
- Industry
- PRAA Finance: Consumer Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- PRAA Finance
- CVAC Health Care
- Exchange
- PRAA Nasdaq
- CVAC Nasdaq
- Market Cap
- PRAA 790.6M
- CVAC 818.8M
- IPO Year
- PRAA N/A
- CVAC 2020
- Fundamental
- Price
- PRAA $18.25
- CVAC $3.23
- Analyst Decision
- PRAA Strong Buy
- CVAC Buy
- Analyst Count
- PRAA 2
- CVAC 2
- Target Price
- PRAA $32.00
- CVAC $10.00
- AVG Volume (30 Days)
- PRAA 328.8K
- CVAC 686.2K
- Earning Date
- PRAA 05-05-2025
- CVAC 04-10-2025
- Dividend Yield
- PRAA N/A
- CVAC N/A
- EPS Growth
- PRAA N/A
- CVAC N/A
- EPS
- PRAA 1.79
- CVAC 0.75
- Revenue
- PRAA $1,114,524,000.00
- CVAC $554,073,921.00
- Revenue This Year
- PRAA $7.67
- CVAC N/A
- Revenue Next Year
- PRAA $5.67
- CVAC $38.07
- P/E Ratio
- PRAA $10.26
- CVAC $4.33
- Revenue Growth
- PRAA 38.87
- CVAC 895.54
- 52 Week Low
- PRAA $15.94
- CVAC $2.22
- 52 Week High
- PRAA $28.64
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- PRAA 48.46
- CVAC 56.34
- Support Level
- PRAA $16.02
- CVAC $3.13
- Resistance Level
- PRAA $18.40
- CVAC $3.32
- Average True Range (ATR)
- PRAA 1.16
- CVAC 0.19
- MACD
- PRAA 0.15
- CVAC 0.04
- Stochastic Oscillator
- PRAA 64.53
- CVAC 83.40
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.